arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Nuwellis, Inc.

NUWE
$4.62 ▼ -0.69 (-12.99%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
63 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

Nuwellis, Inc. faces fundamental challenges with weakness in Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth 14.1% ↘
Op. Margin -160.9% ↗
ROIC 154.2% ↗
FCF / Share $-17.57 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

63-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.97M
↑ +14.1% —
Net Income Profit after all expenses
$-4.54M
↓ -50.7% —
Operating Margin Operating profit as % of sales
-160.9%
↑ +15.3% 1th
FCF / Share Free cash flow per share
$-17.57
↓ -1060.1% —
Long-Term Debt Long-term obligations
$1.97M
↓ -33.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
1
Cash Quality ↓
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 63 quarters